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Objectives: To determine the diagnostic accuracy of fractional exhaled nitric oxide (FENO)
measurement in pneumologists routine diagnostic work-up; and to determine the impact of
the inflammatory pattern on diagnostic accuracy.
Methods: Prospective diagnostic study in 393 patients attending a private practice of pneumol-
ogists with complaints suspicious of obstructive airway disease (OAD). Index test was FENO
measurement. Reference standard was the Tiffeneau ratio (FEV1/VC) or airway resistance as
assessed by whole body plethysmography, with additional bronchoprovocation or bronchodi-
lator testing. Morning sputum was analysed with smear slides which were prepared and stained
by Giemsa.
Results: 154 patients were diagnosed as having asthma (145 diagnoses based on bronchial prov-
ocation, 9 based on bronchodilator results), 5 had COPD. For the whole group, asthma could be
ruled in at FENO > 71 ppb (PPV 80%; 95% CI 63e90%) and ruled out at FENO  9 ppb (NPV 82%;
95% CI 67e91%) (area under the curve (AUC) Z 0.656; 95% CI 0.600e0.712; p < 0.001). 128
patients delivered sputum. FENO was 44.3 ppb (sd 48.9) in patients with predominant eosino-
philic inflammation, 18.5 ppb with neutrophilic inflammation, and 23.1 ppb in others
(pZ 0.003). Diagnostic accuracy of FENO increased when patients with neutrophilic inflamma-
tion were omitted from analysis (AUC Z 0.745; 95% CI 0.651e0.838; p < 0.001). Then asthma
could be ruled in at FENO > 31 ppb (PPV 82%; 95% CI 63e92%) and ruled out at FENO  12 ppb
(NPV 81%; 95% CI 62e91%).614658913; fax: þ49 89 614658915.
r@tum.de (A. Schneider).
2 Published by Elsevier Ltd.
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210 A. Schneider et al.Conclusions: FENO measurement can be useful as an additional diagnostic tool in pneumolo-
gists’ practice. The diagnostic value of FENO could be improved when inflammatory patterns
are taken into account.
ª 2012 Published by Elsevier Ltd.Introduction
Asthma is a common chronic disease with a prevalence of
approximately 5% in industrialized countries.1 It is charac-
terised by chronic inflammation, bronchial hyper-
responsiveness and usually reversible airway obstruction.
Spirometry is considered as a reference standard for diag-
nosing airway obstruction,2 and its accuracy in diagnosing
severe asthma has been demonstrated.3 In mild asthma in
particular, airway obstruction is often not persistent, thus
leading to diagnostic uncertainty.4 Therefore bronchial
provocation remains as a reference standard for determining
bronchial hyper-responsiveness in case of inconclusive
spirometric results.5 Bronchial provocation is, however, time
consuming, costly, not everywhere available, and carries
a small risk of inducing severe bronchospasm.6 Still, bron-
chial provocation is considered to be the best method for
diagnosing asthma,5 despite conflicting evidence probably
arising from differences between the populations studied,7
as the diagnostic value increases with the pre-test proba-
bility of the disease.8 Compared to that, fractional exhaled
nitric oxide (FENO) is a non-invasive, easily availablemarker,
and increased FENO has been consistently demonstrated in
asthma including mild asthma.9;10 Therefore, FENO
measurement helps to include or exclude the diagnosis of
asthma.11 This would allow establishing the diagnosis safely
and fast in general practice and even in private practices of
pneumologists or in hospital without performing bronchial
provocation. The diagnostic accuracy of FENO in asthma has
been investigated in a large number of studies. The results
were generally promising, although quite different cut-off
points for the decision on asthma have been reported.12;13
Until now, inflammatory patterns were rarely taken into
account in studies on the diagnostic accuracy of FENO in
primary care. Airway inflammation in asthma can be
predominantly eosinophilic or non-eosinophilic, including
neutrophilic.14;15 FENO correlates in particular with eosino-
philic inflammation, which explains part of its potential to
assess steroid responses.16e18 TheAmericanThoracic Society
(ATS) Practice Guideline for the interpretation of FENO
recommends a cut-off 47 ppb to predict steroid respon-
siveness.11 On the other hand, neutrophilic inflammation in
asthma could not be detected by elevated FENO.19
This appears relevant, as “non-fitting” values of FENO
are occasionally reported by medical doctors and lead to
confusion. The type of inflammation could induce a dis-
torted estimation of the diagnostic accuracy of FENO,
requiring a different interpretation of its values in different
circumstances. The aim of the present study was to
determine the diagnostic accuracy of FENO within the
pneumologists’ routine work-up of asthma, as well as the
impact of the inflammatory pattern on the diagnostic
accuracy of FENO measurement.Methods
Design and sample
This prospective diagnostic study was performed between
June 2010 and October 2011 in a private practice led by five
pneumologists. Four-hundred patients presenting for the
first time with complaints suggestive of asthma were
consecutively included. Inclusion criteria were the pres-
ence of symptoms such as dyspnoea, cough or phlegm for
more than two months, leading to the clinical suspicion of
obstructive or restrictive airway disease (‘indicated pop-
ulation’). Patients with respiratory tract infections within
the last 6 weeks were excluded. Patients were advised not
to smoke at the day of investigation. When patients were
already using inhaler medication (which could be
prescribed by the general practitioner before referral),
they were advised not use it for twelve hours before lung
function testing. Medical history was recorded using
a structured questionnaire (Table 1).
Patients with previously established diagnosis of chronic
obstructive airway disease were excluded. Other exclusion
criteria related to known contra-indications for broncho-
dilator reversibility testing or bronchial provocation,
namely untreated hyperthyreosis, unstable coronary artery
disease, and cardiac arrhythmia. Pregnancy also led to
exclusion. The study was approved by the Ethics Committee
of the Medical Faculty of the Technische Universita¨t Mu¨n-
chen, and all patients gave their written informed consent.
Based on a previous study, we estimated the pre-test
probability of asthma as 35%.20 Moreover, using a chemo-
luminescence NO analyser and a cut-off value of 46 ppb,
FENO sensitivity had been found to be 32% and specificity
93%.13 Power calculations based on this showed that we
needed at least 302 patients to determine sensitivity and
specificity with 95% confidence intervals of 9%.21
Index test: FENO measurement
All patients underwent standard measurement of FENO
(NioxMino, Aerocrine, Solna, Sweden) at a flow rate of
50 mL/s,22 using feedback signals for control. This was
performed prior to body plethysmography and bronchial
provocation, as the breathing manoeuvres involved could
lead to distorted FENO results.
Reference test: whole body plethysmography
(WBP) and bronchial provocation
Measurements including spirometry were performed
according to standard protocols,23 and reference values
were adapted to sex, age, and height.24 Patients with
Table 1 Characteristics of the study population. Values indicate the number (proportion) or mean (SD); OAD Z obstructive
airway disease; COPD Z chronic obstructive airway disease (n Z 160).
Asthma n (%) COPD n (%) No OAD n (%)
n 154 (39.2) 5 (1.3) 234 (59.5)
Female 91 (59.1) 2 (40.0) 142 (60.7)
FENO (mean in parts per billion [sd]) 42.4 [46.4] 16.6 [6.8] 22.0 [16.5]
Age (mean in years [sd]) 40.5 [15.4] 60.8 [17.0] 44.6 [16.5]
FEV1 (mean of absolute values in litre [sd]) 4.04 [1.05] 2.85 [1.72] 3.97 [1.16]
FEV1 (mean of % of predicted [sd]) 101.3 [17.0] 74.1 [12.3] 107.7 [16.3]
FEV1/VC (mean of % [sd]) 81.8 [8,4] 66.8 [9.8] 85.6 [7.3]
Do you ever suffer from shortness of breath? (yes) 98 (63.6) 5 (100.0) 123 (52.6)
Do you ever suffered from wheezing in your chest? (yes) 97 (62.9) 5 (100.0) 79 (33.8)
Do you often suffer from a cough? (yes) 65 (42.2) 3 (60.0) 112 (47.9)
Do you often suffer from expectoration? (yes) 44 (28.6) 3 (40.0) 58 (24.8)
Have you ever woken up with a feeling of tightness in your chest? (yes) 54 (35.1) 1 (20.0) 59 (25.2)
Have you ever been woken up by an attack of shortness of breath? (yes) 35 (22.7) 1 (20.0) 28 (12.0)
Do you suffer from any nasal allergies? (yes) 76 (49.4) 0 (0) 47 (20.1)
Do you smoke (yes) 19 (12.3) 0 (0) 20 (8.5)
Did you previously smoke? (yes) 56 (36.4) 4 (80.0) 79 (33.8)
How much do/did you smoke? ([mean in pack year (SD)] 10.1 [10.7] 42.5 [3.5] 12.9 [15.8]
FENO measurement and sputum analysis 211FEV1 < 80% predicted received salbutamol with an addi-
tional WBP investigation 20 min later. An obstructive airway
disease was diagnosed if FEV1/VC was 0.70. It was clas-
sified as asthma if clinical symptoms and history fitted and
the change in FEV1 was 12% compared to baseline and
200 mL and lung function returned to the predicted
normal range. An incomplete bronchodilator response was
stated if the response was 12% compared to baseline and
200 mL and lung volumes remained below predicted. It
was classified as COPD, if clinical symptoms and history
fitted and the bronchodilator response of FEV1 after sal-
butamol was <12% compared to baseline and <200 mL2
If there was no bronchial obstruction, bronchial provo-
cation was performed to determine bronchial hyper-
responsiveness (BHR) to methacholine according to the 1-
concentration-4-step dosimeter protocol.25 This yields
similar results as the ATS multi-concentration protocol but
offers advantages in clinical practice.6 An “asthma” diag-
nosis required a 20% fall in FEV1 from baseline after inhaling
methacholine stepwise until the maximum concentration
(16 mg/mL),6;25 alternatively a doubling of airway resis-
tance (Raw) and its increase to 2.0 kPa*s. The responsible
pneumologist was blinded to the FENO results and made the
diagnostic decision only on basis of medical history, phys-
ical examination, spirometry, WBP and bronchial provoca-
tion results.
Spontaneous sputum samples
As described previously patients received a 50 mL tube and
a labelled envelope.26 They were instructed how to
produce spontaneous sputum in the morning at home and to
immediately send the tube to the Cytological Laboratory,
where smear slides were prepared and stained by Giemsa
within one day. The time delay between sputum production
and processing ranged between 24 and 48 h; according to
previous data this did not prevent its usefulness.26 Slides
were first rated for quality (sufficient, limited, not suited)and whether sufficient airway cell numbers were present.
They were then scored semi-quantitatively, as showing
high, medium, or low numbers of inflammatory cells, with
emphasis on eosinophils and neutrophils. The terms eosin-
ophilia and neutrophilia refer to slides with high counts of
these cells. In addition, the presence of tumour cells or
other suspicious alterations was recorded as legally
required.
Data analysis
Baseline data is presented descriptively. Differences
between lung function values (not normally distributed)
were statistically evaluated with the Mann-Whitney-U-Test.
Differences between clinical symptoms were evaluated
with the Chi-Square-Test. Two-by-two contingency tables
of FENO values vs. asthma diagnosis were prepared using
different levels of FENO as cut-off. Sensitivity, specificity
and predictive values were calculated for each cut-off.
Receiver operating characteristic (ROC) curves were
plotted, allowing for a graphical presentation of sensitivity
and specificity. The cut-off points were compared with
respect to their predictive value. One method of identifi-
cation was through the highest sum of sensitivity and
specificity, another to choose a high PPV to rule in and
a high NPV to rule out the disease; both methods were
used. Data was analysed with SPSS 19.0 for Windows, and
95% confidence intervals were calculated using Wilson’s
method.27 Sensitivity analysis to control for confounders
was performed with exclusion of current smokers,28 as well
as exclusion of patients with incomplete bronchodilator
response (which might indicate an overlap between asthma
and COPD). To control for work-up bias, an additional
sensitivity analysis was performed by comparing FENO
values with diagnoses based only on WBP without taking
into account clinical history and symptoms.
The Kruskal-Wallis-Test was employed to compare FENO
values between inflammation patterns. An additional ROC
Figure 1 Flow chart of inclusion and diagnostic work up (OAD Z obstructive airway disease).
212 A. Schneider et al.analysis was calculated for patients who had delivered
sputum, with a sensitivity analysis when patients with
neutrophilia were omitted from the analysis. The ‘number
needed to test’ with the FENO measurement is derived
from the proportion of patients who received a true posi-
tive or true negative diagnosis by FENO measurement in
relation to all patients.
Results
Study population
A total of 400 patients participated (235 [59.8%] female);
the data of 7 patients could not be used due to incom-
pleteness (Fig. 1). Patients mostly complained of shortness
of breath, wheezing and cough (Table 1). Three patients
(0.8%) received a combination of inhaled steroids and long-
acting b-agonists from their general practitioner before
referral to the pneumologists. Five patients (1.3%) received
only short-acting b-agonists, one patient (0.2%) used a long-
acting b-agonist only.
According to the results of lung function tests and
bronchial provocation, 154 patients (39.2%) had asthma, 5Table 2 Relation between sputum cells and FENO; n Z 128 pa
Sputum cells n (%) Asthma n (%) CO
Eosinophils 50 (39.1) 26 (52.0) 1
Neutrophils 19 (14.8) 5 (26.3) 0
Others
(e.g. aerodigestive)
59 (46.1) 23 (39.0) 0
p-value 0.261 (Chi-Square-tes(1.3%) COPD, and 234 (59.5%) no obstructive airway disease
(OAD) (Fig. 1). Of the latter, 13 were diagnosed as having
a restrictive lung disease, 10 chronic bronchitis without
airway obstruction, 30 bronchial hyper-responsiveness
following respiratory tract infection, 28 acute bronchitis,
18 gastro-oesophageal reflux disease, 6 vocal cord
dysfunction, 1 bronchial carcinoma, and 5 chronic cough
due to angiotensin converting enzyme inhibitors. No respi-
ratory disease was found in the remaining 123 patients
(31.3%). Values of FEV1 and VC are given in Table 1.
Three-hundred-sixty-nine patients (93.9%) underwent
bronchial provocation testing. The diagnosis of asthma was
based in 145 (36.9%) patients on provocation results, in 9
(2.2%) on bronchodilator results (BDT). Bronchial provoca-
tion showed a 20% fall of FEV1 in 69 patients, and an at least
doubled increase of Raw to 2 kPa*s (but not 20% fall in
FEV1) in 76 patients. Bronchodilator testing was performed
in 17 patients, showing full response in two patients, while
in another two patients normal values were still not
reached (2 with dyspnoea attacks and allergic rhinitis;
labelled as asthma). 13 patients showed a negative
response; five of these were diagnosed as suffering from
fixed asthma (4 non-smokers, one 25 years old smoker), 5
had COPD, one restrictive lung disorder, one bronchialtients delivered sputum.
PD n (%) No OAD n (%) FENO mean (sd)
(2.0) 23 (46.0) 44.3 (48.9)
(0) 14 (73.7) 18.5 (7.7)
36 (61.0) 23.2 (22.4)
t) 0.002 (Kruskal-Wallis-test)
Figure 2 ROC curves of FENO measurement in the diagnoses
of asthma within different patient samples.
FENO measurement and sputum analysis 213carcinoma and one acute bronchitis. Patients with asthma
were younger than other patients (Table 1).
FENO was highest in asthma and lowest in COPD. 128
patients (32.6%) delivered sputum. 54 of them (42.2%) had
asthma, mostly showing eosinophils (Table 2). Patients with
eosinophilic inflammation showed highest FENO, whereas
those with neutrophilic inflammation showed lowest FENO
(p Z 0.002). Four (21%) patients with neutrophilic cells, 6
(12%) patients with eosinophilic cells, and 3 (5.2%) with
aerodigestive cells were actual smokers (p Z 0.639 in Chi-
Square-Test).Estimates of the diagnostic accuracy of FENO
The results of the ROC analyses are illustrated in Fig. 2. The
area under the curve (AUC) with respect to the whole group
was 0.656 (95% CI 0.600e0.712; p < 0.001). The highest sum
of sensitivity and specificity was reached at a cut-off 25 ppb
(Table 3), and PPV was >80% at a cut-off of 71 ppb,
NPV > 82% at 9 ppb. Thirty-four patients had FENO > 71 ppb
and 38 had FENO < 9 ppb, thus 321 patients (81.7%) showed
in-between FENO results. The discrimination was lower
when current smokers (AUC 0.641; 95% CI 0.579e0.702) or
patients with partial/negative bronchodilator response
(AUC 0.643; 95% CI 0.586e0.700) were omitted (data not
presented). Sensitivity analysis showed that the diagnostic
accuracy was lower, when FENO was compared with diag-
noses established solely on basis of WBP without clinical
interpretation of patient history and symptoms (AUC 0.605;
95% CI 0.547e0.663).
The AUC was 0.724 (95% CI 0.635e0.813; p < 0.001)
when the ROC analysis was performed only in patients who
delivered sputum (n Z 128; prevalence of asthma in this
group 42.2%). Then the highest sum of sensitivity and
specificity was given at cut-off values of 23 ppb and 25 ppb
(Table 3), PPV > 80% at a cut-off of 41 ppb, NPV > 83% at
12 ppb. Twenty patients had FENO > 41 ppb and 29 had
FENO  12 ppb, thus 79 (61.7%) patients had intermediate
FENO results. There was no significant difference between
patients who delivered sputum and those who delivered
not, with respect to lung function [FEV1 (p Z 0.360), VC
(p Z 0.122), FEV1/VC (p Z 0.156)] or clinical symptoms.
When patients with neutrophilia were omitted from the
analysis (n Z 109; remaining prevalence of asthma 45.0%),
the AUC was 0.745 (95% CI 0.651e0.838; p < 0.001). The
highest sum of sensitivity and specificity was reached at
a cut-off of 23 ppb, PPV > 82% at a cut-off point of 31 ppb,
NPV > 81% at 12 ppb. Twenty-seven patients had
FENO > 71 ppb and 26 had FENO  12 ppb, thus 56 (51.4%)
patients had intermediate FENO results.Discussion
As expected from the results of previous diagnostic studies,
the diagnostic accuracy of FENO for asthma was satisfying
when applied to the whole study population. FENO was
significantly reduced in patients with neutrophilic inflam-
matory pattern in their sputum, and the diagnostic accu-
racy increased remarkably when patients with neutrophilia
were omitted.
Table 3 Comparison of the test characteristics at different cut-off points (n Z 160); unit of FENO is parts per billion; PPV is
positive predictive value, NPV is negative predictive value; prev Z prevalence.
Patient group FENO Sensitivity [%]
(95% CI)
Specificity [%]
(95% CI)
PPV [%] (95% CI) NPV [%] (95% CI) n
All patients
n Z 393
prev Z 39%
>9 0.96 (0.91e0.98) 0.13 (0.09e0.18) 0.41 (0.36e0.47) 0.82 (0.67e0.91) 355
>12 0.85 (0.79e0.90) 0.29 (0.23e0.35) 0.43 (0.38e0.49) 0.75 (0.65e0.83) 302
>16 0.70 (0.62e0.76) 0.47 (0.41e0.54) 0.46 (0.40e0.52) 0.71 (0.63e0.77) 233
>20 0.60 (0.52e0.67) 0.63 (0.57e0.69) 0.51 (0.44e0.58) 0.71 (0.64e0.77) 180
>25 0.49 (0.41e0.57) 0.75 (0.69e0.80) 0.56 (0.48e0.64) 0.69 (0.64e0.75) 134
>35 0.33 (0.26e0.40) 0.88 (0.83e0.91) 0.63 (0.52e0.73) 0.67 (0.62e0.72) 79
>41 0.27 (0.21e0.35) 0.92 (0.87e0.94) 0.68 (0.55e0.78) 0.66 (0.61e0.71) 62
>42 0.26 (0.20e0.33) 0.92 (0.87e0.94) 0.67 (0.54e0.77) 0.66 (0.61e0.71) 60
>43 0.25 (0.19e0.33) 0.92 (0.88e0.95) 0.67 (0.55e0.78) 0.66 (0.60e0.71) 60
>44 0.25 (0.19e0.32) 0.92 (0.88e0.95) 0.67 (0.54e0.78) 0.65 (0.60e0.70) 58
>45 0.23 (0.17e0.31) 0.92 (0.88e0.95) 0.66 (0.52e0.77) 0.65 (0.60e0.70) 57
>46 0.27 (0.21e0.35) 0.92 (0.87e0.94) 0.68 (0.55e0.78) 0.66 (0.61e0.71) 55
>71 0.18 (0.12e0.24) 0.97 (0.94e0.99) 0.80 (0.63e0.90) 0.65 (0.60e0.69) 34
All patients who
delivered sputum
n Z 128
prev Z 42%
>9 0.98 (0.90e1.00) 0.14 (0.07e0.23) 0.45 (0.37e0.54) 0.91 (0.62e0.98) 117
>12 0.91 (0.80e0.96) 0.32 (0.23e0.44) 0.49 (0.40e0.59) 0.83 (0.65e0.92) 99
>16 0.76 (0.63e0.85) 0.47 (0.36e0.59) 0.51 (0.40e0.62) 0.73 (0.59e0.83) 80
>20 0.65 (0.51e0.76) 0.62 (0.51e0.72) 0.56 (0.43e0.67) 0.71 (0.59e0.80) 63
>23 0.61 (0.48e0.73) 0.76 (0.65e0.84) 0.65 (0.51e0.76) 0.73 (0.62e0.81) 51
>25 0.56 (0.42e0.68) 0.81 (0.71e0.88) 0.68 (0.53e0.80) 0.71 (0.61e0.80) 44
>35 0.35 (0.24e0.49) 0.92 (0.83e0.96) 0.76 (0.57e0.89) 0.66 (0.56e0.74) 25
>41 0.30 (0.19e0.43) 0.95 (0.87e0.98) 0.80 (0.58e0.92) 0.65 (0.55e0.73) 20
>44 0.26 (0.16e0.39) 0.95 (0.87e0.98) 0.78 (0.55e0.91) 0.64 (0.54e0.72) 18
>47 0.24 (0.15e0.37) 0.95 (0.87e0.98) 0.77 (0.53e0.90) 0.63 (0.54e0.71) 17
>50 0.24 (0.15e0.37) 0.96 (0.89e0.99) 0.81 (0.57e0.93) 0.63 (0.54e0.72) 16
Patients who
delivered sputum;
patients with
neutro-philic cells
omitted
n Z 109
prev Z 45%
>9 0.98 (0.89e1.00) 0.17 (0.09e0.28) 0.49 (0.39e0.59) 0.91 (0.62e0.98) 98
>12 0.90 (0.78e0.96) 0.35 (0.24e0.48) 0.53 (0.42e0.63) 0.81 (0.62e0.91) 83
>16 0.78 (0.64e0.87) 0.43 (0.32e0.56) 0.53 (0.41e0.64) 0.70 (0.54e0.83) 72
>20 0.69 (0.55e0.80) 0.62 (0.49e0.73) 0.60 (0.47e0.71) 0.71 (0.58e0.82) 57
>23 0.67 (0.53e0.79) 0.77 (0.65e0.86) 0.70 (0.56e0.81) 0.74 (0.62e0.83) 47
>31 0.45 (0.32e0.59) 0.92 (0.82e0.96) 0.82 (0.63e0.92) 0.67 (0.56e0.76) 27
>33 0.43 (0.30e0.57) 0.92 (0.82e0.96) 0.81 (0.62e0.92) 0.66 (0.56e0.76) 26
>34 0.41 (0.28e0.55) 0.92 (0.82e0.96) 0.80 (0.61e0.91) 0.65 (0.55e0.75) 25
>35 0.39 (0.26e0.53) 0.92 (0.82e0.96) 0.79 (0.60e0.91) 0.65 (0.54e0.74) 24
>36 0.37 (0.25e0.51) 0.92 (0.82e0.96) 0.78 (0.58e0.90) 0.64 (0.53e0.73) 23
>38 0.37 (0.25e0.51) 0.93 (0.84e0.97) 0.82 (0.61e0.93) 0.64 (0.54e0.74) 22
>40 0.35 (0.23e0.49) 0.93 (0.84e0.97) 0.81 (0.60e0.92) 0.64 (0.53e0.73) 21
214 A. Schneider et al.We found cut-off values with associated sensitivities and
specificities in the range of previously published val-
ues.13,29e31 In the whole group studied by us, 38 patients
showed FENO  9 ppb (NPV  82%) and 34 FENO > 71 ppb
(PPV  80%), respectively. Based on this it can be
concluded that altogether four to five patients have to be
tested with FENO to save one bronchial provocation, as
81.7% had intermediate FENO results. Thus the efficacy is
lower as in a previous trial.13 The ability of FENO to esti-
mate airway inflammation is broadly accepted specifically
for eosinophilic inflammation,11 and FENO corresponds to
eosinophilic cell counts in sputum.19;32;33 However, some
patients might suffer from neutrophilic inflammation, and
FENO might possibly be reduced due to concomitant
oxidant production that lowers the level of FENO.34
Lower values of FENO in the presence of neutrophilia
have already been described19 without elucidating the
impact on cut-off values and the potential use in combi-
nation with other diagnostic information. To clarify thispoint we included sputum analysis. Within the setting of
a clinical practice this could only be realized by analysis of
spontaneous sputum, while allowing for the possibility that
only a part of the population would be able or were willing
to produce such samples. The diagnostic value of sponta-
neous sputum analysis has been demonstrated previously.26
We observed an impact of neutrophilic inflammation on
FENO and consequently on its diagnostic accuracy. The
sensitivity of FENO increased when patients with neutro-
philia were omitted from the ROC analysis, due to
a reduced rate of false negative results. In this case 27
patients had FENO > 71 ppb and 26 had FENO  12 ppb,
thus 56 (51.4%) patients had intermediate FENO results.
Therefore, only two patients need to be investigated with
FENO to save one bronchial provocation.
Our findings might also be a cue that FENO is helpful in
both eosinophilic and neutrophilic airway inflammation, if
considered in combination with other diagnostic data and
not as an isolated cut-off value. It has been repeatedly
FENO measurement and sputum analysis 215advocated that diagnosis and assessment of asthma activity
should be based on a panel of diagnostic measures, as often
one method alone will not cover all relevant aspects of the
disease.11 This becomes obvious when a neutrophilic airway
inflammation pattern dominates the disease thereby dis-
torting the results of FENO measurement. “Non-fitting” low
FENO values might be of importance for patients with
strong clinical hints for asthma, in whom one might be
inclined to state a failure of FENO. In these cases, spon-
taneous sputum analysis might be added to ascertain the
diagnosis of neutrophilic asthma. Future trials on the
diagnostic value of FENO in clinical settings should probably
take into account these considerations.
One limitation is that only a third of the patients delivered
sputum. Moreover, the groupwith neutrophilic inflammation
was small. This might limit the evaluation of the method and
the potential generalisation of the present results. The AUC
increased with respect to the selection of patients who
delivered sputum. However, we found no cues that these
patients might show more severe disease than the other
patients. Another limitation is the correct classification of
patients with incomplete bronchodilator response. One way
for differentiation would have been a long-term follow-up
with a trial of steroids, which was not possible in our study
design. However, the sensitivity analyses suggested that this
did not disturb the estimation of the diagnostic accuracy of
FENO. Further studies under different settings might check
the relationship between FENO and inflammatory asthma
phenotype and whether it has implications for therapy.
There is conflicting evidence about the adequate cut-off-
point for methacholine challenges, possibly due to differ-
ences regarding study populations and disease severity.7,8
The lack of consensus is reflected by the use of different
diagnostic cut-off values,5,35,36 compared to the 16 mg/dl
cut-off.6 Moreover, the use of data from lung function and
bronchial provocation testingwas partially informal based on
the long-term experience of the pneumologists. This could
not be avoided in order not to interfere too much with the
diagnostic work-up and customs. However, each diagnosis
was reviewed by an external expert team (AS, RAJ) to guar-
antee for valid diagnostic decision making. The sensitivity
analyses showed indeed that thediagnostic accuracyof FENO
improved when lung function results were interpreted in the
light of medical history and clinical signs and symptoms.
To conclude, the predictive value of FENO in clinical
practice might be rather low when the pre-test probability
of asthma is low in the respective clinical setting despite
the satisfying diagnostic accuracy. However, our results
suggest that the diagnostic value of FENO could be mark-
edly improved when inflammatory patterns are taken into
account. Specifically, low FENO values in patients with
clear clinical and functional signs of asthma point towards
predominantly neutrophilic instead of eosinophilic airway
inflammation. This might be useful for clinicians who are
confronted with seemingly “non-fitting” FENO values in
patients with asthma. This should, however, be investi-
gated in further studies.
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